Patent ID: 8475813
Filing Date: 2013-07-02
Classification: A61K,A61M,A61P

Abstract:
1. An oral dosage form, comprising an osmotic device comprising a core comprising gabapentin, and a semipermeable membrane surrounding the core, wherein the semipermeable membrane comprises a plasticizer, is permeable to a fluid in an environment of use and is substantially impermeable to unsolubilized gabapentin, wherein the oral dosage form as formulated is of sufficient size to promote retention in the stomach of a subject in the fed mode for a period of at least about 5 hours, wherein the dosage form is a tablet comprising about 100 mg to about 4800 mg gabapentin, wherein the gabapentin is released into the upper gastrointestinal tract over a period of about 5-12 hours at a rate sufficient to achieve a lower maximum plasma concentration (C